Back to results
US 12,715,921 B2Granted
Anti-PD-1 antibodies for treatment of lung cancer
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsPetra Rietschel, Israel Lowy
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., lung cancer). The methods of the present invention comprise administering a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody), to a subject with lung cancer wherein the cancer tissue expresses PD-L1.
Claims31
A method of treating non-small cell lung cancer (NSCLC) or increasing the survival of a patient with NSCLC, comprising:
- (a) selecting a patient with NSCLC, wherein the patient has tested negative for epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) translocations and ROS1 fusions;
- and
- (b) administering one or more doses of a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds programmed death 1 (PD-1) to the patient, thereby treating NSCLC in the patient;
- wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) of a heavy chain variable region (HCVR) and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) of a light chain variable region (LCVR), wherein HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 3;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 4;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 5;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 6;
- LCDR2 comprises the amino acid sequence of AAS;
- and LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 8.
11 more elements
A method for treating non-small cell lung cancer (NSCLC) or increasing the survival of a patient with NSCLC, comprising:
- (a) selecting a patient with NSCLC, wherein the patient is selected on the basis of at least one attribute selected from the group consisting of:
- (i) the patient has advanced or metastatic NSCLC;
- (ii) the patient has squamous or non-squamous stage III or stage IV NSCLC;
- (iii) the patient has not been previously treated with a systemic treatment for NSCLC;
- and (iv) the patient has been previously treated with an anti-tumor therapy;
- (b) determining if the patient has tested negative for epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) translocations and ROS1 fusions;
- and
- (c) administering one or more doses of a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds PD-1 to the patient, if the patient has tested negative for EGFR mutations, ALK translocations and ROS1 fusions, thereby treating NSCLC in the patient;
- wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) of a heavy chain variable region (HCVR) and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) of a light chain variable region (LCVR), wherein HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 3;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 4;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 5;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 6;
- LCDR2 comprises the amino acid sequence of AAS;
- and LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 8.
16 more elements
A method of treating non-small cell lung cancer (NSCLC) or increasing the survival of a patient with NSCLC, comprising:
- (a) selecting a patient with NSCLC, wherein the patient has tested negative for epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) translocations and ROS1 fusions;
- and
- (b) administering one or more doses of a therapeutically effective amount of an antibody that specifically binds programmed death 1 (PD-1) to the patient, thereby treating NSCLC in the patient;
- wherein the anti-PD-1 antibody comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) of a heavy chain variable region (HCVR) and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) of a light chain variable region (LCVR), wherein HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 3;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 4;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 5;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 6;
- LCDR2 comprises the amino acid sequence of AAS;
- and LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 8.
11 more elements
Dependencies are inferred from the claim text.